mRna, MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between…
Tumore, MD Anderson e CureVac insieme per il vaccino a mRna
L’Università del Texas MD Anderson Cancer Center e CureVac N.V. hanno annunciato oggi un accordo di co-sviluppo e licenza per sviluppare nuovi vaccini contro il cancro a base di mRNA.…